Leigongteng (Radix et Rhizoma Tripterygii) via compatibility with Jinqiancao (Herba Lysimachiae): its toxicity-reduced efficacy in H22-bearing mice

Wang Junming, Li Jinhua, Cai Hong, Zhang Yueyue, Li Jinyang, Cui Ying

**Abstract**

**OBJECTIVE:** To observe toxicity-reduced effects of Leigongteng (Radix et Rhizoma Tripterygii) (LGT) via compatibility with Jinqiancao (Herba Lysimachiae) (JQC) in H22-bearing mice and investigate the possible underlying mechanism, and further explore whether JQC can enhance LGT-evoked anti-tumor effect.

**METHODS:** H22-bearing mice were orally administered with LGT alone and its compatibility with JQC, and tumors, serum, livers and kidneys were collected to evaluate the toxicity-reduced efficacy and the possible mechanism.

**RESULTS:** LGT evoked significantly elevated biochemical indicators including serum alanine/ aspartate transaminase (ALT/AST), creatinine (Cr) and urea nitrogen (BUN) as well as pathological damage in mice, which were all obviously reversed by JQC via compatibility at the ratios from 4/1 to 1/4. Further analysis indicated that pro-inflammatory cytokine tumor necrosis factor-alpha (TNF-α), and malondialdehyde (MDA) levels significantly decreased, while anti-inflammatory cytokine interleukin (IL)-10, and glutathione (GSH), GSH-s transferase (GST), GSH peroxidase (GSH-Px), superoxide dismutase (SOD) and catalase (CAT) levels all increased in livers and kidneys of mice. Besides, after compatibility with JQC at the ratios of 4/1, 2/1, 1/1, 1/2 and 1/4, LGT-decreased tumor weight was further decreased by 48.4%, 57.3%, 54.0%, 49.3% and 52.9%, respectively (all \( P < 0.01 \)).

**CONCLUSION:** JQC could reduce LGT-induced hepatotoxicity and nephrotoxicity, and enhance the antitumor efficacy via compatibility with JQC, and the toxicity-reduced mechanism could involve inhibiting hepatic and kidney oxidative stress and inflammation.

© 2019 JTCM. All rights reserved.

**Keywords:** Celastraceae; Primulaceae; Toxicity tests; Oxidative stress; Inflammation

**INTRODUCTION**

Leigongteng (Radix et Rhizoma Tripterygii) (LGT) is widely used in Traditional Chinese Medicine (TCM) as a medicinal plant with prominent clinical efficacy such as anti-cancers, anti-diabetic nephropathy, anti-rheumatoid arthritis, etc. However, it can also often
caused seriously toxic side effects reported during used in clinic.\textsuperscript{57} Compatibility is one of the characteristics of TCM, meanwhile also the main form of TCM.\textsuperscript{64} TCM theory thinks that it, through appropriate compatibility, can play a role in reducing toxicity or enhancing efficacy.\textsuperscript{65} In TCM, that LGT is combined with Jinqiancao (Herba Lysimachiae) (JQC), which has diverse and broad bioactivities including hepatoprotection,\textsuperscript{10} anti-oxidation,\textsuperscript{11} anti-inflammation,\textsuperscript{43} etc., belongs to compatibility of mutual suppression of Chinese medicinal, and JQC can reduce the toxicity induced by LGT via proper compatibility.\textsuperscript{13} In folk medicine, it has been reported that JQC can alleviate toxicity when poisoning occurs due to the application of LGT.\textsuperscript{15} However, until now, the toxicity-reduced efficacy of LGT via compatibility with JQC and its possible mechanism are still unknown. Furthermore, whether JQC augments LGT-induced anti-tumor activity is unclear as well. This study is carried out to observe the toxicity-reduced efficacy of LGT by JQC via compatibility and the potential mechanism, and further explore whether JQC can enhance LGT-inhibited tumor growth.

MATERIALS AND METHODS

Experimental animals

Kunming (KM) male mice (18-22 g) were obtained from Experimental Animal Center of Henan Province (Zhengzhou, China). Animals were given rodent laboratory chow and water ad libitum and maintained under controlled conditions with a temperature of (22 ± 1) °C, relative humidity of 60% ± 10%, and a 12/12 h light/dark cycle (lights on at 7:00 A.M.). All the procedures were in strict accordance with the P.R. China legislation on the use and care of laboratory animals and guidelines formulated by the Institute for Experimental Animals of Henan University of Chinese Medicine, and were approved by the university committee for animal experiments.

Cell lines

Mouse H22 tumor cells were collected from H22 tumor-bearing mice which were purchased from the Institute of Chinese Materia Medica, China Academy of Chinese Medical Sciences (Beijing, China). Mouse H22 tumor cells were maintained in the peritoneal cavities of male KM mice in the Laboratory of Experimental Animals of Henan University of Chinese Medicine (Zhengzhou, China).

Reagents

Kits including alanine / aspartate transaminase (ALT/AST), creatinine (Cr), urea nitrogen (BUN), malondialdehyde (MDA), glutathione-s transferase (GST), glutathione peroxidase (GSH-Px), superoxide dismutase (SOD) and catalase (CAT) were all purchased from Nanjing Jiancheng Bioengineering Institute (Nanjing, China). Mouse tumor necrosis factor-alpha (TNF-α) and interleukin (IL)-10 enzyme-linked immunosorbent assay (ELISA) kits were provided by Boster Biological Technology (Wuhan, China).

Plant material and Preparations of extracts

LGT were obtained from Taining County of Fujian province (Taining, China). JQC origins in Sichuan Province and was purchased from a traditional drug store, Henan Materia Medica Chain Co., Ltd. (Zhengzhou, Henan province, P.R. China). LGT and JQC were both identified by Prof. Sui-Qing Chen (Pharmacognosy Department, Henan University of Chinese Medicine, Zhengzhou, Henan province, P.R. China). The preparations of the ethyl acetate extracts from LGT and its compatibility with JQC were described as follows.

Ethyl acetate extracts (EAEs) from LGT and its compatibility with JQC (mass ratios from 1/4 to 4/1) were obtained by reflux extraction once 2 h for repeated three times, and the ethyl acetate was recovered under reduced pressure and dried in vacuo (60 °C) to obtain dry extract. The EAEs yields of LGT and its different ratios combined with JQC (LGT/JQC; 4/1, 2/1, 1/1, 1/2 and 1/4) were 29.70, 27.25, 42.95, 39.28, 34.03 and 44.31 mg/g raw medicinal materials, respectively. In order to make the quality of the prepared extracts controllable, we determined the contents of triptolide and celastrol as the main active and toxic chemical components\textsuperscript{4,5} of LGT by high-performance liquid chromatography (HPLC). The contents of triptolide in above extracts were 10.605, 2.013, 0.783, 2.031, 2.827, and 0.167 mg/g, and those of celastrol were 3.995, 0.722, 0.118, 0.060, 0.345 and 0.219 mg/g, respectively, as assayed by the analysis of high-performance liquid chromatography (HPLC).

Treatment protocol

Ascites of the mouse H22 were drawn out from mice under aseptic conditions. Cells were promptly diluted 2 times with aseptic saline. The diluted H22 cell suspension was inoculated subcutaneously (0.2 mL per mouse) into the right armpit. One day after inoculation, mice, except for the normal (non-tumor-inoculated) animals, were randomly divided into eight groups of ten mice each. The control (tumor-inoculated) groups of mice received daily oral administration of 0.5% (5 g/L) sodium carboxyl methyl cellulose (CMC-Na; 0.2 mL/10 g). The other six groups received LGT and different ratios of LGT vs JQC (4/1, 2/1, 1/1, 1/2 and 1/4) by intragastric administration (ig) for 13 d starting from 24 h after tumor inoculation. The doses of LGT and its each compatibility with JQC were all 60 mg/kg according to LGT at the same equivalent. After treatment, mice were sacrificed by cervical dislocation after peripheral blood samples, livers, kidneys, and tumors were collected at 24 h...
Our results showed that LGT reduced the activities of JQC reverses LGT-decreased main antioxidant enzymes levels all decreased significantly (all \( \sigma < 0.01 \)) in liver and kidney tissues of mice treated with LGT compared with control groups, while the compatibility with JQC under all combined ratios (LGT/JQC from 4/1 to 1/4) prevented these elevation (all \( P < 0.01 \)).

**JQC reverses LGT-decreased GSH and it-related enzymes levels**

In the current research, the GSH and it-related enzymes levels all decreased significantly (all \( P < 0.01 \)) in liver and kidneys of mice treated with LGT alone, while the compatibility with JQC under four combined ratios (LGT/JQC from 2/1 to 1/4) significantly reversed these reduction in livers and kidneys (for GSH: \( P < 0.01 \), \( P < 0.01 \), \( P < 0.05 \), \( P < 0.05 \) respectively, for GST and GSH-Px: all \( P < 0.01 \)) (Figure 3C-D, 4A-D), and that under the combined ratio of 4/1 also significantly reversed the reduction of GSH and GSH-Px in livers (Figure 3C, 4C) and GST and GSH-Px in kidneys (Figure 4B, 4D).

**JQC reverses LGT-decreased main antioxidant enzymes SOD and CAT levels**

Our results showed that LGT reduced the activities of...
Figure 1 Effects of compatibility with JQC on serum ALT, AST, Cr, and BUN levels in LGT-administered H22-bearing mice.

H22 tumor-bearing mice were orally administered with Leigongteng (Radix et Rhizoma Tripterygii) (LGT) and its compatibility with Jinqiancao (Herba Lysimachiae) (JQC) for 13 d at the same dose of 60 mg/kg. ALT: alanine transaminase; AST: aspartate transaminase; Cr: creatinine; BUN: urea nitrogen. Data are presented as mean ± standard deviation (n = 10). Significant differences compared with the normal group were designated as a P < 0.01 and e P < 0.05, with control as b P < 0.01 and d P < 0.05, and with LGT alone group as c P < 0.01.

Figure 2 Effects of compatibility with JQC on histopathology for livers (from A to H) and for kidneys (from I to P) by HE×200 in LGT-administered H22-bearing mice.

H22 tumor-bearing mice were orally administered with Leigongteng (Radix et Rhizoma Tripterygii) (LGT) and its compatibility with Jinqiancao (Herba Lysimachiae) (JQC) for 13 d at the same dose of 60 mg/kg. Histological sections were stained with hematoxylin and eosin (HE) for the observation under the 200 times light microscopy.
Our results indicated that LGT significantly elevated hepatic and kidney SOD and CAT levels (all P < 0.01) (Figure 5A-D), and that under combined ratio of 4/1 also obviously inhibited the LGT-induced reduction in hepatic CAT, kidney SOD and CAT levels (all P < 0.01) (Figure 5B-D).

Effects of JQC on TNF-α and IL-10 levels of livers and kidneys
Our results indicated that LGT significantly elevated liver and kidney pro-inflammatory cytokine TNF-α (both P < 0.01) and decreased anti-inflammatory cytokine IL-10 (both P < 0.01) levels in mice, while the compatibility with JQC under four combined ratios (LGT/JQC from 2/1 to 1/4) prevented such significant reduction (all P < 0.01) (Figure 6A-D), and that under combined ratio of 4/1 also conspicuously inhibited LGT-evoked abnormality in hepatic IL-10, kidney TNF-α and IL-10 levels (all P < 0.01) (Figure 6B-D).

JQC enhances LGT-induced anti-tumor efficacy
The effect of JQC on the anti-tumor activity of LGT
LGT-evoked significant elevation of se-
P < 0.57%
and
44.8%,
tumor weight was further decreased by
and/
1.7) by
showed that LGT decreased tumor weight of tu-
22
data presented as mean ± standard deviation (n = 10). Significant differences compared with the normal group were designated as *P < 0.01 and *P < 0.05, with control as **P < 0.01 and ***P < 0.05, and with LGT alone group as ****P < 0.01.

in transplanted H22 is shown in Figure 7. Our results showed that LGT decreased tumor weight of tu-
p < 0.01) by 39.7%. After treatment with JQC at the ratios of 4/1, 2/1, 1/1, 1/2 and 1/4, compared with LGT alone, LGT-decreased tumor weight was further decreased by 48.4%, 57.3%, 54.0%, 49.3% and 52.9%, respectively (all

**DISCUSSION**

In the study, LGT-evoked significant elevation of se-
rum ALT, AST, BUN and Cr levels, while after compat-
bility with JQC their elevation was obviously reversed. The result indicated that LGT-induced hepatotoxicity and nephrotoxicity were attenuated by JQC via compat-
ibility, which was further confirmed by the histo-
pathological analysis. Actually, JQC-contained bioac-
tive chemical compounds including quercetin, chloro-
genic acid and rutin all had hepatoprotective and renal-
protective properties. The attenuation in this study
may be related to the combined effects of quercetin,
chlorogenic acid and rutin contained in JQC and trip-
tolide, the major toxic compound of LGT. As for how
in livers and kidneys of H₂₂-bearing mice, treated the LGT-evoked decreased activities of GST and GSH-Px.

GST and GSH-Px are cellular glutathione-related antioxidants, the enzymes involved the protection of JQC against LGT-evoked liver and kidney oxidative injury. SOD and CAT both play important roles in the enzymatic defenses of the cells against oxidative stress injury. SOD, a metalloenzyme, can convert O₂⁻ generated in the process of the oxidative stress to hydrogen peroxide.\(^{20,21}\) CAT mainly presents in the peroxisomes of all aerobic cells and serves to protect the cells against the damage of hydrogen peroxide by catalyzing it into molecular oxygen and water without producing toxic free radicals.\(^{20,21}\) As peroxisomes are abundant in proteins, where oxidative stress always happens, thus CAT is a classical oxidative biomarker. Our results showed that JQC reversed LGT-reduced enzymatic levels of SOD and CAT, suggesting that JQC protect against LGT-evoked liver and kidney oxidative stress injury, while SOD and CAT both taken part in such protection.

Cytokines, generated by virtually every nucleated cell in the body, are pleiotropic, regulatory peptides and include many types of hepatocytes and nephrocytes.\(^{22-24}\) The cytokine families contain several subfamilies including the interleukins, the tumor necrosis factor (TNF) family, chemokines, colony-stimulating factors and others.\(^{22-24}\) Among them, at least two different cytokines from different cytokine families, namely the pro-inflammatory molecule TNF-α and the anti-inflammatory cytokine IL-10, have emerged as vital factors in many aspects of liver and kidney diseases.\(^{22-25}\) In the current study, JQC significantly reversed the LGT-evoked excessively increased TNF-α and decreased IL-10 levels in H₂₂-bearing mice, indicating that pro- and anti-inflammatory cytokines could involve the protection of JQC against LGT-evoked liver and kidney injury.

After confirming that the toxicity of LGT can be inhibited by JQC via compatibility, we further investigated the effect of the compatibility of the two on the antitumor activity of LGT. The results showed that, after compatibility with JQC, not only could reduce the toxicity of LGT, but also enhance the anti-tumor activity of LGT. The results showed that, after compatibility with JQC, not only could reduce the toxicity of LGT, but also enhance the anti-tumor activity of LGT. Actually, JQC-contained bioactive chemical compounds including quercetin, chlorogenic acid and rutin all had anticancer properties.\(^{26-27}\) The enhanced efficacy in this study could be associated with the combined effects of quercetin, chlorogenic acid and rutin contained in JQC, and triptolide and celastrol, the main anticancer active compounds of LGT. However, the effect of JQC alone on H₂₂ tumor-bearing mice was not tested here, which is a limitation of the current study.

In conclusion, the present research demonstrates that LGT-evoked hepatotoxicity and nephrotoxicity can be attenuated by JQC via compatibility, and the mechanisms underlying can be likely to involve inhibiting LPO, enhancing GSH, GSH-related and antioxidant-related enzymes, regulating pro- and anti-inflammatory cytokines levels (at least reducing TNF-α and elevating IL-10 levels) and thus ameliorates LGT-in-
duced toxicity. Besides, the anti-tumor activity of LGT could be also enhanced by compatibility with JQC.

REFERENCES


31. Kaffe ET, Rigopoulos EL, Koukoulis GK, Dalekos GN, Moulas AN. Oxidative stress and antioxidant status in pa-
Wang JM et al. / Research Article


